Status:
UNKNOWN
Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised Study
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Lymphoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This randomised study aimed at evaluating the medical and economical impact of positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) in the therapeutic prescription in patient...
Eligibility Criteria
Inclusion
- Age over 18, with Hodgkin's lymphoma or with large B and P cell non-Hodgkin's lymphoma, or after a first-line chemotherapy with at least a residual mass or after induction chemotherapy or at progression.
- Stem cell transplantation would be programmed. Patients were required to give their written informed consent.
Exclusion
- Progressive cancer or diagnosed less than 5 years, except cancer in situ of the cervix and basocell skin carcinoma, kidney insufficiency or diabetes. Patients would not be pregnant or lactating
Key Trial Info
Start Date :
February 1 2002
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00169598
Start Date
February 1 2002
Last Update
April 27 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gilles Salles
Lyon, France, 69495